Infectious Complications after Haploidentical Hematopoietic Stem Cells Transplantation in Patients with High-Risk Tumors of Hematopoietic and Lymphoid Tissues: A Single-Center Experience

YuS Osipov1, SS Bessmeltsev2, GN Salogub1, VV Ivanov1, ES Mikhailov1, NA Zhukova1, AV Chechetkin2

1 VA Almazov National Medical Research Center, 2 Akkuratova str., Saint Petersburg, Russian Federation, 197341

2 Russian Research Institute of Hematology and Transfusiology, 16 2-ya Sovetskaya str., Saint Petersburg, Russian Federation, 191024

For correspondence: Yurii Sergeevich Osipov, 2 Akkuratova str., Saint Petersburg, Russian Federation, 197341; Tel.: +7(812)702-37-65; e-mail:

For citation: Osipov YuS, Bessmeltsev SS, Salogub GN, et al. Infectious Complications after Haploidentical Hematopoietic Stem Cells Transplantation in Patients with High-Risk Tumors of Hematopoietic and Lymphoid Tissues: A Single-Center Experience. Clinical oncohematology. 2019;12(4):406–15 (In Russ).

DOI: 10.21320/2500-2139-2019-12-4-406-415


Aim. To determine the incidence of viral, bacterial, and fungal infections in post-transplant period and to assess the prognostic value of infections and their influence on early and long-term results of haploidentical hematopoietic stem cells transplantation (haplo-HSCT).

Materials & Methods. Retrospective study included 61 patients older than 18 years with high-risk oncohematological diseases. In the period from 2015 to 2018 all patients received haplo-HSCT. Median follow-up after haplo-HSCT was 12.5 months (376 days, range 6–1202). Patients were divided into two groups. The first group (n = 26) received haplo-HSCT as salvage therapy. It included patients with refractory tumors without remission by the start of haplo-HSCT and patients with early relapses after HLA-matched related or unrelated allo-HSCT. The second group (n = 35) received haplo-HSCT on reaching the optimal pretransplant status (“non-salvage”).

Results. The incidence of cytomegalovirus (CMV) reactivation, invasive mycosis, and bacterial infections was 70.4 %, 11.5 %, and 75.4 %, respectively. CMV reactivation and invasive mycosis did not affect either the 35- or the 100-day overall survival (OS). For the first time bacterial infections were stratified based on severity according to Sepsis 3 consensus, which allowed to identify groups of patients with unfavorable prognosis. Severe bacterial infections (sepsis and septic shock) correlated with worse early and long-term results, especially in patients without remission by the start of haplo-HSCT, whereas febrile neutropenia/bloodstream infection did not affect OS. On the whole, mortality associated with bacterial infections was 26.2 %.

Conclusion. The main factor affecting early lethality after haplo-HSCT is a severe bacterial infection. The key risk factor is lack of remission by the start of haplo-HSCT. Sepsis 3 criteria can be applied in the period of postcytostatic cytopenia to identify the group of patients with most unfavorable prognosis (septic shock). The implementation of current infection control methods (genotyping of multiple drug resistant strains and timely determining the strategy of antimicrobial chemotherapy on the basis of the results obtained) into everyday clinical practice can improve the treatment outcomes in this category of patients.

Keywords: haploidentical hematopoietic stem cells transplantation, infectious complications, sepsis, septic shock, cytomegalovirus reactivation, invasive mycosis.

Received: April 11, 2019

Accepted: September 18, 2019

Read in PDF


  1. Поп В.П., Рукавицын О.А. Аллогенная трансплантация гемопоэтических стволовых клеток: перспективы и альтернативы, собственный опыт. Российский журнал детской онкологии и гематологии. 2017;4(2):46–69. doi: 10.17650/2311-1267-2017-4-2-46-69.

    [Pop VР, Rukavitsyn OА. Allogeneic transplantation of hematopoietic stem cells: Perspectives and alternatives, own experience. Russian Journal of Children Hematology and Oncology. 2017;4(2):46–69. doi: 10.17650/2311-1267-2017-4-2-46-69. (In Russ)]

  2. Luznik L, O’Donnell PV, Ephraim JF. Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical Bone Marrow Transplantation. Semin Oncol. 2012;39(6):683–93. doi: 10.1053/j.seminoncol.2012.09.005.

  3. Luznik L, Fuchs EJ. High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation. Immunol Res. 2010;47(1–3):65–77. doi: 10.1007/s12026-009-8139-0.

  4. Burroughs LМ, O’Donnell PV, Sandmaier BM, et al. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following non-myeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transplant. 2008;14(11):1279–87. doi: 10.1016/j.bbmt.2008.08.014.

  5. Pagliardini T, Harbi S, Furst S, et al. Post-transplantation cyclophosphamide-based haploidentical versus Atg-based unrelated donor allogeneic stem cell transplantation for patients younger than 60 years with hematological malignancies: a single-center experience of 209 patients. Bone Marrow Transplant. 2018;54(7):1067–76. doi: 10.1038/s41409-018-0387-y.

  6. Kasamon Y, Luznik L, Leffell M, et al. Nonmyeloablative HLA-haploidentical Bone Marrow Transplantation with high-dose post-transplantation cyclophosphamide: effect of HLA disparity on outcome. Biol Blood Marrow Transplant. 2010;16(4):482–9. doi: 10.1016/j.bbmt.2009.11.01

  7. Бессмельцев С.С., Абдулкадыров К.М. Множественная миелома: руководство для врачей. М.: СИМК, 2016. 512 с.

    [Bessmeltsev SS, Abdulkadyrov KM. Mnozhestvennaya mieloma: rukovodstvo dlya vrachei. (Multiple myeloma: manual for physicians.) Moscow: SIMK Publ.; 2016. 512 p. (In Russ)]

  8. Галстян Г.М., Макарова П.М., Кузьмина Л.А. и др. Успешная трансплантация аллогенного костного мозга у больных с тяжелым грамотрицательным сепсисом и септическим шоком. Клиническая онкогематология. 2014;7(2):122–30.

    [Galstyan GM, Makarova PM, Kuzmina LA, et al. Successful allogeneic bone marrow transplantation in patients with severe gram-negative sepsis and septic shock. Klinicheskaya onkogematologiya. 2014;7(2):122–30. (In Russ)]

  9. Fayard A, Daguenet E, Blaise D, et al. Evaluation of infectious complications after haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide following reduced-intensity and myeloablative conditioning: a study on behalf of the Francophone Society of Stem Cell Transplantation and Cellular Therapy (SFGM-TC). Bone Marrow Transplant. 2019. [ahead of print] doi: 10.1038/s41409-019-0475-7.

  10. Kumar G, Ahmad S, Taneja A, et al. Severe sepsis in hematopoietic stem cell transplant recipients. Crit Care Med. 2015;43(2):411–21. doi: 10.1097/ccm.0000000000000714.

  11. Omrani AS, Almaghrabi RS. Complications of hematopoietic stem cell transplantation: Bacterial infections. Hematol Oncol Stem Cell Ther. 2017;10(4):228–32. doi: 10.1016/j.hemonc.2017.05.018.

  12. Alhemmari SH, Refaat SM, Abdullah AA, Abul M. Infectious complications after allogeneic bone marrow transplantation: Sheikha Badryia Center, Kuwait. Gulf J Oncol. 2015;1(18):79–86.

  13. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin Infect Dis. 2011;52(4):е56–е93. doi: 10.1093/cid/cir073.

  14. EORTC International Antimicrobial Therapy Cooperative Group. Gram-positive bacteraemia in granulocytopenic cancer patients. Eur J Cancer Clin Oncol. 1990;26(5):569–74. doi: 10.1016/0277-5379(90)90079-9.

  15. Klastersky J. Science and pragmatism in the treatment and prevention of neutropenic infection. J Antimicrob Chemother. 1998;41(Suppl 4):13–24. doi: 10.1093/jac/41.suppl_4.13.

  16. Mikulska M, Viscoli C, Orasch C, et al. Aetiology and resistance in bacteraemias among adult and paediatric haematology and cancer patients. J Infect. 2014;68(4):321–31. doi: 10.1016/j.jinf.2013.12.006.

  17. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009;15(10):1143–238. doi: 10.1016/j.bbmt.2009.06.019.

  18. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46(12):1813–21. doi: 10.1086/588660.

  19. Abraham E. New Definitions for Sepsis and Septic Shock: Continuing Evolution but With Much Still to Be Done. JAMA. 2016;315(8):757–9. doi: 10.1001/jama.2016.0290.

  20. Gustinetti G, Mikulska M. Bloodstream infections in neutropenic cancer patients: a practical update. Virulence. 2016;7(3):280–97. doi: 10.1080/21505594.2016.1156821.

  21. Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis. 2003;36(9):1103–10. doi: 10.1086/374339.

Infectious Complications in Multiple Myeloma Patients Receiving Various Antitumor Regimens

AA Novikova, GA Klyasova, EO Gribanova, VV Ryzhko, TA Tupoleva, LP Mendeleeva, VG Savchenko

National Medical Hematology Research Center, 4a Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167

For correspondence: Anna Aleksandrovna Novikova, 4a Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167; Tel.: +7(916)873-15-72; e-mail:

For citation: Novikova AA, Klyasova GA, Gribanova EO, et al. Infectious Complications in Multiple Myeloma Patients Receiving Various Antitumor Regimens. Clinical oncohematology. 2019;12(2):231–9.

DOI: 10.21320/2500-2139-2019-12-2-231-239


Aim. To study infectious complications and factors attributable to them as reported in multiple myeloma (MM) patients in the framework of state-of-the-art anticancer therapy.

Materials & Methods. The study included MM patients who received regimens based on bortezomib, lenalidomide, and bendamustine from January 2013 to August 2018. The regimens including thalidomide, melphalan, and aggressive antitumor treatment constituted the group of “others”.

Results. The study enrolled 174 patients (82 men and 92 women with median age of 61 years) with newly diagnosed MM (with median follow-up of 5.6 months). A total of 1362 courses of antitumor treatment were administered: 895 bortezomib (n = 174), 306 lenalidomide (n = 68), and 63 bendamustine (n = 22) regimens. The category of “others” included 98 treatment courses (n = 34). Infectious complications were reported in 129 (74.1 %) MM patients throughout the period of 344 (25.3 %) courses of antitumor treatment. Infection incidence on bortezomib (24.4 %), lenalidomide (20.3 %), and bendamustine (27 %) therapies was similar, and fell clearly below the infection incidence registered on the regimens constituting the group of “others” (48 %; р < 0.01). The most common infectious complications were pneumonias (54.9 %), urinary (24.7 %), and herpesviral infections (22.9 %). Herpesviral infections were predominantly associated with bortezomib treatment (29.8 %; p < 0.05). Significant factors (р < 0.05) associated with infection development were leukopenia, the presence of central venous catheter (CVC), need for blood transfusion, MM progression or relapse.

Conclusion. Infection incidence in MM patients receiving bortezomib, lenalidomide, and bendamustine anticancer therapy appeared to be similar, but considerably lower than in patients who received antitumor regimens belonging to category “others”. The prevalent type of infectious complications was pneumonia. Herpesviral infections were most common on bortezomib regimens. Factors related to infection development throughout all therapies were leukopenia, the presence of CVC, need for blood transfusion, MM progression or relapse.

Keywords: multiple myeloma, infectious complications, risk factors.

Received: January 26, 2019

Accepted: March 29, 2019

Read in PDF 


  1. Mateos MV, Ocio EM, San Miguel JF. Novel generation of agents with proven clinical activity in multiple myeloma. Semin Oncol. 2013;40(5):618–33. doi: 10.1053/j.seminoncol.2013.07.005.

  2. Kurtin SE, Bilotti E. Novel agents for the treatment of multiple myeloma: proteasome inhibitors and immunomodulatory agents. J Adv Pract Oncol. 2013;4(5):307–21. doi: 10.6004/jadpro.2013.4.5.3.

  3. Diehl V, Cheson BD. Bendamustine in the treatment of hematologic malignancies. Introduction. Semin Oncol. 2002;29(4, Suppl 13):1–3.

  4. Gentile M, Vigna E, Recchia AG, et al. Bendamustine in multiple myeloma. Eur J Haematol. 2015;95(5):377–88. doi: 10.1111/ejh.12609.

  5. Klein NC, Go CH-U, Cunha BA. Infections associated with steroid use. Infect Dis Clin N Am. 2001;15(2):423–32. doi: 10.1016/s0891-5520(05)70154-9.

  6. Менделеева Л.П., Покровская О.С., Рехтина И.Г. Протокол диагностики и лечения множественной миеломы. В кн.: Алгоритмы диагностики и протоколы лечения заболеваний системы крови. Под ред. В.Г. Савченко. М.: Практика, 2018. Т. 2. С. 405–96.

    [Mendeleeva LP, Pokrovskaya OS, Rekhtina IG. Diagnosis and treatment protocol in multiple In: Savchenko VG, ed. Algoritmy diagnostiki i protokoly lecheniya zabolevanii sistemy krovi. (Diagnostic algorithms and treatment protocols for blood system diseases.) Moscow: Praktika Publ.; 2018. Vol. 2. pp. 405–96. (In Russ)]

  7. Nucci M, Anaissie E. Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clin Infect Dis. 2009;49(8):1211–25. doi: 10.1086/605664.

  8. Teh BW, Harrison SJ, Allison CC, et al. Predicting risk of infection in patients with newly diagnosed multiple myeloma: utility of immune profiling. Front Immunol. 2017;8:1247. doi: 10.3389/fimmu.2017.01247.

  9. Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–e548. doi: 10.1016/S1470-2045(14)70442-5.

  10. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer. 1975;36(3):842–54. doi: 10.1002/1097-0142(197509)36:3<842::aid-cncr2820360303>;2-u.

  11. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412–20. doi: 10.1200/JCO.2005.04.242.

  12. Rajkumar SV, Richardson P, San Miguel JF. Guidelines for determination of the number of prior lines of therapy in multiple myeloma. Blood. 2015;126(7):921–22. doi: 10.1182/blood-2015-05-647636.

  13. Клясова Г.А., Охмат В.А. Антимикробная терапия. В кн.: Алгоритмы диагностики и протоколы лечения заболеваний системы крови. Под ред. В.Г. Савченко. М.: Практика, 2018. Т. 2. С. 1067–113.

    [Klyasova GA, Okhmat VA. Antimicrobial therapy. In: Savchenko VG, ed. Algoritmy diagnostiki i protokoly lecheniya zabolevanii sistemy krovi. (Diagnostic algorithms and treatment protocols for blood system diseases.) Moscow: Praktika Publ.; 2018. Vol. 2. pp. 1067–113. (In Russ)]

  14. Teh BW, Harrison SJ, Wort LJ, et al. Risks, severity and timing of infections in patients with multiple myeloma a longitudinal cohort study in the era of immunomodulatory drug therapy. Br J Haematol. 2015;171(1):100–8. doi: 10.1111/bjh.13532.

  15. Valkovic T, Gacic V, Ivandic J, et al. Infections in hospitalised patients with multiple myeloma: main characteristics and risk factors. Turk J Hematol. 2015;32(3):234–42. doi: 10.4274/tjh.2013.0173.

  16. de la Rubia J, Cejalvo MJ, Ribas P. Infectious complications in patients with newly diagnosed multiple myeloma: A complication from the past? Leuk Lymphoma. 2015;57(2):258–68. doi: 10.3109/10428194.2015.1088647.

  17. Ying L, YinHui T, Yunliang Z, Sun H. Lenalidomide and the risk of serious infection in patients with multiple myeloma: a systematic review and meta-analysis. Oncotarget. 2017;8(28):46593–600. doi: 10.18632/oncotarget.16235.

  18. Ponisch W, Mitrou PS, Merkle K, et al. Treatment of Bendamustine and Prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with Melphalan and Prednisone – a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO). J Cancer Res Clin Oncol. 2006;132(4):205–12. doi: 10.1007/s00432-005-0074-4.

  19. Blimark C, Holmberg E, Mellqvist UH, et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica. 2015;100(1):107–13. doi: 10.3324/haematol.2014.107714.

  20. Teh BW, Slavin MA, Harrison SJ, Worth LJ. Prevention of viral infections in patients with multiple myeloma: the role of antiviral prophylaxis and immunization. Expert Rev Anti Infect Ther. 2015;13(11):1325–36. doi: 10.1586/14787210.2015.1083858.

  21. Li J, Li Y, Huang B, et al. Drug-induced modulation of T lymphocytes as a potential mechanism of susceptibility to infections in patients with multiple myeloma during bortezomib therapy. Cell Biochem Biophys. 2015;71(1):457–64. doi: 10.1007/s12013-014-0224-x.

  22. Kim SJ, Kim K, Kim BS, et al. Bortezomib and the increased incidence of herpes zoster in patients with multiple myeloma. Clin Lymph Myel. 2008;8(4):237–40. doi: 10.3816/CLM.2008.n.031.

Diagnostic Value of C-Reactive Protein as Marker of Infections in Patients with De Novo Acute Myeloid Leukemias

L.N. Tarasova1, S.G. Vladimirova1, V.V. Cherepanova2

1 Kirov Scientific Research Institute for Hematology and Blood Transfusion under the Federal Medico-Biological Agency of Russia, 72 Krasnoarmeiskaya str., Kirov, Russian Federation, 610027

2 Municipal Hospital No. 33, 54 pr-t Lenina, Nizhny Novgorod, Russian Federation, 603122

For correspondence: Lyudmila Nikolaevna Tarasova, DSci, Professor, 72 Krasnoarmeiskaya str., Kirov, Russian Federation, 610027; Tel.: +7(8332)67-57-00; e-mail:

For citation: Tarasova LN, Vladimirova SG, Cherepanova VV. Diagnostic Value of C-Reactive Protein as Marker of Infections in Patients with De Novo Acute Myeloid Leukemias. Clinical oncohematology. 2015;8(4):442–446 (In Russ).

DOI: 10.21320/2500-2139-2015-8-4-442-446


Aim. To determine diagnostically relevant C-protein levels (CRP) as an early infection marker in patients with de novo acute myeloid leukemias (AML), to evaluate the dependence of CRP concentrations on the WBC count and leukemic blast cells in the peripheral blood.

Methods. CRP was tested in 39 patients with de novo AML (17 males and 22 females) at the age of 20 to 76 years (median age is 49). AML types according to the FAB grading were as follows: М0 — 2, М1 — 4, М2 — 23, М4 — 8, and М5 — 2 patients.

Results. CRP concentrations in patients without symptoms of an infection (n = 16) were within the range from 0 to 43 mg/l (median 5.5 mg/l). The Spearman’s rank correlation coefficients between the CRP level and WBC and blast cell counts were 0.664 (= 0.006) and 0.473 (= 0.062), respectively. The obtained data confirm activation of CRP synthesis in case of leukemia. In patients with an infection and/or fever (n = 23), CRP levels were significantly higher than those in patients without an infection: 8–383 mg/l (median 81 mg/l). No correlation between the CRP level and WBC and blast cell counts was found. Therefore, the CRP synthesis during the onset of AML is significantly increased as a response to the infection. In groups of patients with and without infections, 95% CI were equal to 0–40 mg/l and 12–315 mg/l, respectively. Since they overlap within the range from 12 to 40 mg/l, they may be considered a «grey zone». The CRP concentrations within this range suggest infection. CRP levels lower than 12 mg/l or higher than 40 mg/l with a high degree of probability confirm either absence or presence of infectious complications, respectively.

Conclusion. Therefore, CRP is an accessible and informative marker of infection in patients with AML during the onset of the disease. Monitoring of its levels permits to start a timely antimicrobial therapy; at that, the efficacy of the therapy can be assessed based on the dynamics of this parameter.

Keywords: acute myeloid leukemias, infectious complications, acute-phase proteins, C-reactive protein, blast cells, white blood cells.

Received: April 20, 2015

Accepted: October 22, 2015

Read in PDF (RUS)pdficon


  1. Абдулкадыров К.М., Чуданова Т.В. Диагностика и лечение бактериальных и микотических инфекций у больных гемобластозами. Вестник гематологии. 2005;1(3):5–13. [Abdulkadyrov KM, Chudanova TV. Diagnosis and treatment of bacterial and mycotic infections in patients with hemoblastoses. Vestnik gematologii. 2005;1(3):5–13. (In Russ)]
  2. Галстян Г.М., Городецкий В.М., Шулутко Е.М. и др. Полиорганная патология при септическом шоке у больных с гемобластозами. Анестезиология и реаниматология. 2000;2:36–40. [Galstyan GM, Gorodetskii VM, Shulutko EM, et al. Multiple organ impairment associated with septic shock in patients with hemoblastoses. Anesteziologiya i reanimatologiya. 2000;2:36–40. (In Russ)]
  3. Черепанова В.В., Перевалова Н.Н., Тарасова Л.Н. и др. Нарушения гемостаза у больных острым миелобластным лейкозом в процессе полихимиотерапии. Гематология и трансфузиология. 2004;49(5):27–33. [Cherepanova VV, Perevalova NN, Tarasova LN, et al. Impairment of hemostasis in patients with acute myeloblastic leukemia during polychemotherapy. Gematologiya i transfuziologiya. 2004;49(5):27–33. (In Russ)]
  4. Паровичникова Е.Н., Савченко В.Г., Исаев В.Г. и др. Итоги многоцентрового рандомизированного исследования по лечению острых миелоидных лейкозов взрослых. Терапевтический архив. 2007;79(7):14–9. [Parovichnikova EN, Savchenko VG, Isaev VG, et al. Results of multicenter, randomized study to treat acute myeloid leukemia in adults. Terapevticheskii arkhiv. 2007;79(7):14–9. (In Russ)]
  5. Птушкин В.В., Багирова Н.С. Инфекционные осложнения у больных с онкогематологическими заболеваниями. В кн.: Клиническая онкогематология: руководство для врачей. Под ред. М.А. Волковой. М.: Медицина, 2001. С. 507–28. [Ptushkin VV, Bagirova NS. Infectious complications in patients with oncohematological malignancies. In: Volkova MA, ed. Klinicheskaya onkogematologiya: rukovodstvo dlya vrachei. (Clinical oncohematology: manual for physicians.) Moscow: Meditsina Publ.; 2001. p. 507–28. (In Russ)]
  6. Альес В.Ф., Миронов П.И., Шадчнев А.П. Этиология, эпидемиология и классификация сепсиса у детей. Анестезиология и реаниматология. 2002;1:63–6. [Al’es VF, Mironov PI, Shadchnev AP. Etiology, epidemiology, and classification of sepsis in children. Anesteziologiya i reanimatologiya. 2002;1:63–6. (In Russ)]
  7. Levy MN, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med. 2003;31(4):1250–6. doi: 10.1097/01.ccm.0000050454.01978.3b.
  8. Белобородова Н.В., Попов Д.А. Диагностическая ценность некоторых маркеров инфекции в раннем послеоперационном периоде у кардиохирургических больных. Анестезиология и реаниматология. 2005;3:45–9. [Beloborodova NV, Popov DA. Diagnostic value of several infection markers during early postoperation period in cardiosurgical patients. Anesteziologiya i reanimatologiya. 2005;3:45–9. (In Russ)]
  9. Миронов И.П., Цыденжапов Е.Ц., Михельсон В.А. Эволюция терминологии сепсиса у детей в последнее десятилетие. Анестезиология и реаниматология. 2006;1:69–73. [Mironov IP, Tsydenzhapov ETs, Mikhel’son VA. Evolution of sepsis terminology in children over last decade. Anesteziologiya i reanimatologiya. 2006;1:69–73. (In Russ)]
  10. Abraham E, Matthay MF, Dinarello CA. Consensus Conference Definitions For Sepsis, Septic Shock, Acute Lung Injury And Acute Respiratory Distress Syndrome: Time For A Reevaluation. Crit Care Med. 2000;28(1):232–5. doi: 10.1097/00003246-200001000-00039.
  11. Титов В.Н., Близнюков О.П. С-реактивный белок: физико-химические свойства, методы определения и диагностическое значение. Клиническая лабораторная диагностика. 2004;4:3–9. [Titov VN, Bliznyukov OP. C-reactive protein: physico-chemical properties, test methods and diagnostic value. Klinicheskaya laboratornaya diagnostika. 2004;4:3–9. (In Russ)]
  12. Шепеленко А.Ф., Хацкевич В.Л., Лищенюк О.А. и др. Роль гуморальных маркеров активности воспаления в оценке адекватности стартовой антибактериальной химиотерапии внебольничной пневмонии. Военно-медицинский журнал. 2005;1:25–30. [Shepelenko AF, Khatskevich VL, Lishchenyuk OA, et al. Role of humoral markers of activity of inflammation in assessment of starting antibacterial chemotherapy of community-acquired pneumonia. Voenno-meditsinskii zhurnal. 2005;1:25–30. (In Russ)]
  13. Lopez JV, Rojo JM, Rodriguez OM, et al. Fever In Emergency Department: Screening For Severe Disease. Rev Clin Esp. 2008;208(3):130–4. doi: 10.1157/13115820.
  14. Тарасова Л.Н., Черепанова В.В., Мустафина Г.Н., Владимирова С.Г. С-реактивный белок как маркер инфекции у больных острым миелобластным лейкозом. Гематология и трансфузиология. 2009;54(5):27–31. [Tarasova LN, Cherepanova VV, Mustafina GN, Vladimirova SG. C-reactive protein as marker of infection in patients with acute myeloblast leukemia. Gematologiya i transfuziologiya. 2009;54(5):27–31. (In Russ)]
  15. Simon L, Gauvin F, Amre DK, et al. Serum procalcitinin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Bacter Dis. 2004;39:206–17. doi: 10.1086/421997.
  16. Владимирова С.Г., Тарасова Л.М., Скольская О.Ю., Черепанова В.В. С-реактивный белок как маркер тяжести инфекционного процесса у больных острым миелоидным лейкозом при нейтропении. Терапевтический архив. 2013;85(11):34–40. [Vladimirova SG, Tarasova LM, Skol’skaya OYu, Cherepanova VV. C-reactive protein as marker of severity of infection in patients with acute myeloid leukemia in neutropenia. Terapevticheskii arkhiv. 2013;85(11):34–40. (In Russ)]
  17. Владимирова С.Г., Тарасова Л.М., Докшина И.А., Черепанова В.В. Оценка чувствительности и специфичности метода определения С-реактивного белка при диагностике инфекционных осложнений у больных острым лимфобластным лейкозом, получающих химиотерапию. Клиническая лабораторная диагностика. 2014;59(11):17–21. [Vladimirova SG, Tarasova LM, Dokshina IA, Cherepanova VV. Evaluation of sensitivity and specificity of test method for C-reactive protein in diagnosis of infectious complications in patients with acute lymphoblast leukemia on chemotherapy. Klinicheskaya laboratornaya diagnostika. 2014;59(11):17–21. (In Russ)]
  18. Антонов В.Г., Козлов В.К. Патогенез онкологических заболеваний: иммунные и биохимические феномены и механизмы. Внеклеточные и клеточные механизмы общей иммунодепрессии и иммунной резистентности. Цитокины и воспаление. 2004;3(1):8–19. [Antonov VG, Kozlov VK. Pathogenesis on oncological diseases: immune and biological phenomena and mechanisms. Extracellular and cellular mechanisms of general immunosuppression and immune resistance. Tsitokiny i vospalenie. 2004;3(1):8–19. (In Russ)]
  19. Kwaan HC. Double hazard of thrombophilia and bleeding in leukemia. Hematol ASH Educ Book. 2007;1:151–7. doi: 10.1182/asheducation-2007.1.151.
  20. Галстян Г.М., Берковский А.Л., Зуева А.В. и др. Фактор некроза опухоли, интерлейкин-6, эндотоксин и прокальцитонин при септическом шоке у больных с опухолевыми заболеваниями системы крови. Терапевтический архив. 2002;74(7):56–61. [Galstyan GM, Berkovskii AL, Zueva AV, et al. Tumor necrosis factor, interleukin-6, endotoxin, and procalcitonin in septic shock in patients with hematological malignancies. Terapevticheskii arkhiv. 2002;74(7):56–61. (In Russ)]
  21. Carrigan SD, Scott G, Tabrizian M. Toward resolving the challenges of sepsis diagnosis. Clin Chem. 2004;50(8):1301–14. doi: 10.1373/clinchem.2004.032144.
  22. Косякова Н.И., Прохоренко С.В., Прохоренко И.Р. Дисбаланс продукции цитокинов у больных тяжелым хирургическим сепсисом. Иммунология. 2005;5:319–21. [Kosyakova NI, Prokhorenko SV, Prokhorenko IR. Disbalance of cytokine production in patients with severe surgical sepsis. Immunologiya. 2005;5:319–21. (In Russ)]
  23. Козлов В.К. Дисфункция иммунной системы в патогенезе сепсиса: возможности диагностики. Цитокины и воспаление. 2006;5(2):15–28. [Kozlov VK. Immune system dysfunction in pathogenesis of sepsis: possibilities of diagnosis. Tsitokiny i vospalenie. 2006;5(2):15–28. (In Russ)]
  24. ГОСТ Р 53022. Технологии лабораторные клинические. Требования к качеству клинических лабораторных исследований. Часть 3. Правила оценки клинической информативности лабораторных тестов. М., 2008. [GOST Р 53022. Clinical laboratory technologies. Requirements to quality of clinical laboratory investigations. Part 3. Guidelines for evaluation of clinical information value of lab tests. Moscow; 2008. (In Russ)]
  25. Клясова Г.А. Антимикробная терапия. В кн.: Программное лечение заболеваний системы крови: сборник алгоритмов диагностики и протоколов лечения заболеваний системы крови. Под ред. В.Г. Савченко. М.: Практика, 2012. С. 829–53. [Klyasova GA. Antimicrobial therapy. In: Savchenko VG, ed. Programmnoe lechenie zabolevanii sistemy krovi: sbornik algoritmov diagnostiki i protokolov lecheniya zabolevanii sistemy krovi. (Program treatment of hematological diseases: collection of algorithms of diagnosing and treatment protocols of hematological diseases.) Moscow: Praktika Publ.; 2012. p. 829–53. (In Russ)]